Skip to main content

Table 1 Patient demographics, vaccine history, and symptoms

From: Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections

Sample Sex Age Height (cm) Weight (kg) Vaccine received First dose Second dose Symptoms Comorbidities† N1 qPCR Ct Day of positive test Clinical outcome
Patient 0a Male 67–69 177.8 81.6 Covaxin BBV152 2021-03-02 2021-03-31 Fever, cough, body aches, fatigue, loss of taste and/or smell, Shortness of breath at rest, Shortness of breath with activity None 29 Day 4 Deceased
Patient 0b Female 65–70 152.4 53 Covaxin BBV152 2021-03-02 2021-03-30 Fever, cough, body aches, fatigue, loss of taste and/or smell, Shortness of breath at rest, Shortness of breath with activity Diabetes 27 Day 4 Recovered
Patient 1 Male 60–66 172 68 Pfizer BNT162b2 2021-12-30 2021-01-20 Cough, fatigue None 17 Day 4 Recovered
Patient 2 Male 59–64 170.1 77 Pfizer BNT162b2 2021-01-07 2021-01-28 Fever, cough, fatigue Hypertension 24 Day 5 Recovered
Patient 3 Female 51–56 155 63.5 Moderna mRNA-1273 2020-12-30 2021-01-26 Fever, cough, body aches, fatigue, loss of taste and/or smell Overweight 25 Day 5 Recovered
Patient 4 Female 51–56 162.6 88.5 Moderna mRNA-1273 2021-01-04 2021-02-01 Fatigue, loss of taste and/or smell Overweight 22 Day 5 Recovered
  1. As defined by the Centers for Disease Control and Prevention